The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Varenicline, an α4β2 Nicotinic Acetylcholine Receptor Partial Agonist, vs Sustained-Release Bupropion and Placebo for Smoking Cessation<SUBTITLE>A Randomized Controlled Trial</SUBTITLE>
Abstract
CONTEXT: The alpha4beta2 nicotinic acetylcholine receptors (nAChRs) are linked to the reinforcing effects of nicotine and maintaining smoking behavior. Varenicline, a novel alpha4beta2 nAChR partial agonist, may be beneficial for smoking cessation. OBJECTIVE: To assess efficacy and safety of varenicline for smoking cessation compared with sustained-release bupropion (bupropion SR) and placebo. DESIGN, SETTING, AND PARTICIPANTS: Randomized, double-blind, parallel-group, placebo- and active-treatment-controlled, phase 3 clinical trial conducted at 19 US centers from June 19, 2003, to April 22, 2005. Participants were 1025 generally healthy smokers (> or =10 cigarettes/d) with fewer than 3 months of smoking abstinence in the past year, 18 to 75 years old, recruited via advertising. INTERVENTION: Participants were randomly assigned in a 1:1:1 ratio to receive brief counseling and varenicline titrated to 1 mg twice per day (n = 352), bupropion SR titrated to 150 mg twice per day (n = 329), or placebo (n = 344) orally for 12 weeks, with 40 weeks of nondrug follow-up. MAIN OUTCOME MEASURES: Primary outcome was the exhaled carbon monoxide-confirmed 4-week rate of continuous abstinence from smoking for weeks 9 through 12. A secondary outcome was the continuous abstinence rate for weeks 9 through 24 and weeks 9 through 52. RESULTS: For weeks 9 through 12, the 4-week continuous abstinence rates were 44.0% for varenicline vs 17.7% for placebo (odds ratio [OR], 3.85; 95% confidence interval [CI], 2.70-5.50; P<.001) and vs 29.5% for bupropion SR (OR, 1.93; 95% CI, 1.40-2.68; P<.001). Bupropion SR was also significantly more efficacious than placebo (OR, 2.00; 95% CI, 1.38-2.89; P<.001). For weeks 9 through 52, the continuous abstinence rates were 21.9% for varenicline vs 8.4% for placebo (OR, 3.09; 95% CI, 1.95-4.91; P<.001) and vs 16.1% for bupropion SR (OR, 1.46; 95% CI, 0.99-2.17; P = .057). Varenicline reduced craving and withdrawal and, for those who smoked while receiving study drug, smoking satisfaction. No sex differences in efficacy for varenicline were observed. Varenicline was safe and generally well tolerated, with study drug discontinuation rates similar to those for placebo. The most common adverse events for participants receiving active-drug treatment were nausea (98 participants receiving varenicline [28.1%]) and insomnia (72 receiving bupropion SR [21.9%]). CONCLUSION: Varenicline was significantly more efficacious than placebo for smoking cessation at all time points and significantly more efficacious than bupropion SR at the end of 12 weeks of drug treatment and at 24 weeks. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00141206.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Varenicline, a nicotinic acetylcholine receptor (nAChR) partial agonist, is reported to increase continuous abstinence rates to ∼50% following 12 weeks of treatment, which is significantly better than bupropion (∼30%) or placebo (∼18%”
From Parallel Anxiolytic-Like Effects and Upregulation of Neuronal Nicotinic Acetylcholine Receptors Following Chronic Nicotine and Varenicline (2011) · cites this paper as Gonzales et al., 2006
In the citing paper
“Varenicline, a partial agonist at the α4β2 nAChRs, and a full agonist at the α7 nAChRs, is a new, efficacious treatment for nicotine dependence (4–6).”
From Varenicline improves mood and cognition during smoking abstinence (2009) · cites this paper as [4]
In the citing paper
“These trials document treatment-related reductions in smoking urges and withdrawal-related negative affect (4, 5, 9), as well as reduced smoking reward during a lapse (10).”
From Varenicline improves mood and cognition during smoking abstinence (2009) · cites this paper as [4]
In the citing paper
“The effects of varenicline on subjective abstinence symptoms were of a magnitude similar to those observed in clinical efficacy trials (4, 36).”
From Varenicline improves mood and cognition during smoking abstinence (2009) · cites this paper as [4]
In the citing paper
“Individuals who relapsed derived less enjoyment from smoking while taking varenicline [241].”
From Mechanistic insights into nicotine withdrawal (2011) · cites this paper as [241]
In the citing paper
“Nearly one quarter (21–23%) of patients taking varenicline for a short period of time (12 weeks) maintained abstinence at 52 weeks of follow-up.”
From Mechanistic insights into nicotine withdrawal (2011) · cites this paper as [241]
In the citing paper
“Gonzales and colleagues [241] found a similar decrease in negative affect, but also found a significant decrease in restlessness in patients taking varenicline.”
From Mechanistic insights into nicotine withdrawal (2011) · cites this paper as [241]
In the citing paper
“This represents a significant improvement over sustained-release bupropion (14–16%) and placebo (8–10%).”
From Mechanistic insights into nicotine withdrawal (2011) · cites this paper as [241]
In the citing paper
“Two large, randomized, placebo-controlled studies released in 2006 related the efficacy of varenicline to that of bupropion in aided smoking cessation [233, 241].”
From Mechanistic insights into nicotine withdrawal (2011) · cites this paper as [241]
In the citing paper
“numerous studies have shown that varenicline, a Food and Drug Administration-approved drug widely used to help people quit smoking, potently acts as a partial agonist at ␣42* nAChRs”
From Varenicline Is a Potent Partial Agonist at α6β2* Nicotinic Acetylcholine Receptors in Rat and Monkey Striatum (2012) · cites this paper as Gonzales et al., 2006
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. B. (2013) · Oxford University Press eBooks · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,845
The Fagerstrom Test for Nicotine Dependence: a revision of the Fagerstrom Tolerance Questionnaire
HEATHERTON, T. F., KOZLOWSKI, L. T., FRECKER, R. C., & FAGERSTROM, K. (1991) · British Journal of Addiction · doi:10.1111/j.1360-0443.1991.tb01879.x · Cited by 10,738
Signs and Symptoms of Tobacco Withdrawal
Hughes, J. R. (1986) · Archives of General Psychiatry · doi:10.1001/archpsyc.1986.01800030107013 · Cited by 1,669
A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation
Jorenby, D. E., Leischow, S. J., Nides, M. A., Rennard, S. I., Johnston, J. A., Hughes, A. R., Smith, S. S., Muramoto, M. L., Daughton, D. M., Doan, K., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903043400903 · Cited by 1,585
Cigarette Smoking Among Adults--United States, 2003
(2005) · JAMA · doi:10.1001/jama.294.2.172 · Cited by 1,520
Cox, L. S., Tiffany, S. T., & Christen, A. G. (2001) · Nicotine & Tobacco Research · doi:10.1080/14622200020032051 · Cited by 1,188
Effects of nicotine on the nucleus accumbens and similarity to those of addictive drugs.
Pontieri, F. E., Tanda, G., Orzi, F., & Chiara, G. D. (1996) · Nature · doi:10.1038/382255a0 · Cited by 1,073
Jasinski, D. R. (1978) · Archives of General Psychiatry · doi:10.1001/archpsyc.1978.01770280111012 · Cited by 782
Fiore, M. (2000) · Respiratory care · doi:10.1177/002013240004501006 · Cited by 773
Flagged first, then by citations
Cited by
Sorted by citations
Items 201–300 of 1,000
Johnson, P. M., Hollander, J. A., & Kenny, P. J. (2008) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2008.03.024 · Cited by 90
Brain Stimulation Methods to Treat Tobacco Addiction
Wing, V. C., Barr, M. S., Wass, C., Lipsman, N., Lozano, A. M., Daskalakis, Z. J., & George, T. P. (2012) · Brain stimulation · doi:10.1016/j.brs.2012.06.008 · Cited by 88
van Schayck, O. C. P., Williams, S., Barchilon, V., Baxter, N., Jawad, M., Katsaounou, P. A., Kirenga, B., Panaitescu, C., Tsiligianni, I., Zwar, N. A., et al. (2017) · npj Primary Care Respiratory Medicine · doi:10.1038/s41533-017-0039-5 · Cited by 87
Smoking-the Bane of Wound Healing
Ahn, C., Mulligan, P., & Salcido, R. (2008) · Advances in Skin & Wound Care · doi:10.1097/01.asw.0000305440.62402.43 · Cited by 87
Stopping smokeless tobacco with varenicline: randomised double blind placebo controlled trial
Fagerström, K., Gilljam, H., Metcalfe, M., Tonstad, S., & Messig, M. (2010) · BMJ · doi:10.1136/bmj.c6549 · Cited by 87
The Return on Investment of a Medicaid Tobacco Cessation Program in Massachusetts
Richard, P., West, K., & Ku, L. (2012) · PLoS ONE · doi:10.1371/journal.pone.0029665 · Cited by 86
Varenicline Augmentation in Depressed Smokers: An 8-Week, Open-Label Study
Philip, N. S., Carpenter, L. L., Tyrka, A. R., Whiteley, L. B., & Price, L. H. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04441 · Cited by 86
2011 WRITING GROUP MEMBERS*, Rooke, T. W., Hirsch, A. T., Misra, S., Sidawy, A. N., Beckman, J. A., Findeiss, L., Golzarian, J., Gornik, H. L., Halperin, J. L., et al. (2011) · Catheterization and Cardiovascular Interventions · doi:10.1002/ccd.23373 · Cited by 85
Antidepressants for smoking cessation
Hajizadeh, A., Howes, S., Theodoulou, A., Klemperer, E., Hartmann-Boyce, J., Livingstone-Banks, J., & Lindson, N. (2023) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000031.pub6 · Cited by 84
Genetics and Smoking Cessation
Lerman, C. E., Schnoll, R. A., & Munafo, M. R. (2007) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2007.09.006 · Cited by 88
Feng, B., Obach, R., Burstein, A., Clark, D., de Morais, S., & Faessel, H. M. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100405 · Cited by 85
Efficacy and Safety of Varenicline for Smoking Cessation
Hays, J. T., Ebbert, J. O., & Sood, A. (2008) · The American Journal of Medicine · doi:10.1016/j.amjmed.2008.01.017 · Cited by 84
Factors associated with the use of aids to cessation in English smokers
Kotz, D., Fidler, J., & West, R. (2009) · Addiction · doi:10.1111/j.1360-0443.2009.02639.x · Cited by 85
Developing and Validating a Human Laboratory Model to Screen Medications for Smoking Cessation
McKee, S. A., Weinberger, A. H., Shi, J., Tetrault, J. M., & Coppola, S. (2012) · Nicotine & Tobacco Research · doi:10.1093/ntr/nts090 · Cited by 84
Asthana, A., Johnson, H. M., Piper, M. E., Fiore, M. C., Baker, T. B., & Stein, J. H. (2010) · American Heart Journal · doi:10.1016/j.ahj.2010.06.006 · Cited by 83
Comparison of expired carbon monoxide and plasma cotinine as markers of cigarette abstinence
Jatlow, P. I., Toll, B. A., Leary, V., Krishnan‐Sarin, S., & O’Malley, S. S. (2008) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2008.05.013 · Cited by 82
Sleep as a Target for Optimized Response to Smoking Cessation Treatment
Patterson, F., Grandner, M. A., Malone, S. K., Rizzo, A., Davey, A., & Edwards, D. G. (2017) · Nicotine & Tobacco Research · doi:10.1093/ntr/ntx236 · Cited by 84
Nicotine in Senescence and Atherosclerosis
Centner, A. M., Bhide, P. G., & Salazar, G. (2020) · Cells · doi:10.3390/cells9041035 · Cited by 86
Rooke, T. W., Hirsch, A. T., Misra, S., Sidawy, A. N., Beckman, J. A., Findeiss, L., Golzarian, J., Gornik, H. L., Halperin, J. L., Jaff, M. R., et al. (2011) · Vascular Medicine · doi:10.1177/1358863x11424312 · Cited by 83
The Health Effect of Psychostimulants: A Literature Review
Favrod-Coune, T., & Broers, B. (2010) · Pharmaceuticals · doi:10.3390/ph3072333 · Cited by 84
Nicotinic acetylcholine receptors: an overview on drug discovery
D’hoedt, D., & Bertrand, D. (2009) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728220902841045 · Cited by 79
A Review of Tobacco Use Treatments in U.S. Ethnic Minority Populations
Cox, L. S., Okuyemi, K. S., Choi, W. S., & Ahluwalia, J. S. (2011) · American Journal of Health Promotion · doi:10.4278/ajhp.100610-lit-177 · Cited by 79
Role of the Glutamatergic System in Nicotine Dependence
Liechti, M. E., & Markou, A. (2008) · CNS Drugs · doi:10.2165/00023210-200822090-00001 · Cited by 79
Smith, R. C., Amiaz, R., Si, T., Maayan, L. A., Jin, H., Boules, S., Sershen, H. W., Li, C., Ren, J., Liu, Y., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0143490 · Cited by 83
Definition of Best Medical Treatment in Asymptomatic and Symptomatic Carotid Artery Stenosis
Paraskevas, K. I., Mikhailidis, D. P., Veith, F. J., & Spence, J. D. (2015) · Angiology · doi:10.1177/0003319715624526 · Cited by 80
Turner, J. R., Castellano, L. M., & Blendy, J. A. (2011) · Nicotine & Tobacco Research · doi:10.1093/ntr/ntq206 · Cited by 78
LeSage, M. G., Shelley, D., Ross, J. T., Carroll, F. I., & Corrigall, W. A. (2008) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2008.08.024 · Cited by 79
Changes in plasma brain-derived neurotrophic factor levels in smokers after smoking cessation
Bhang, S., Choi, S., & Ahn, J. (2009) · Neuroscience Letters · doi:10.1016/j.neulet.2009.10.046 · Cited by 79
Combination treatment with varenicline and nicotine replacement therapy
Ebbert, J. O., Burke, M. V., Hays, J. T., & Hurt, R. D. (2009) · Nicotine & Tobacco Research · doi:10.1093/ntr/ntp042 · Cited by 77
Varenicline in the treatment of tobacco dependence
Fagerström, K. O. (2008) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s927 · Cited by 78
Effect of Varying Levels of Disease Management on Smoking Cessation
Ellerbeck, E. F., Mahnken, J. D., Cupertino, A. P., Cox, L. S., Greiner, K. A., Mussulman, L. M., Nazir, N., Shireman, T. I., Resnicow, K., & Ahluwalia, J. S. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-7-200904070-00003 · Cited by 77
Effect of night smoking, sleep disturbance, and their co-occurrence on smoking outcomes.
Peters, E. N., Fucito, L. M., Novosad, C., Toll, B. A., & O’Malley, S. S. (2011) · Psychology of Addictive Behaviors · doi:10.1037/a0023128 · Cited by 76
Psychedelics as an emerging novel intervention in the treatment of substance use disorder: a review
Divito, A. J., & Leger, R. F. (2020) · Molecular Biology Reports · doi:10.1007/s11033-020-06009-x · Cited by 78
Carpenter, M. J., Jardin, B. F., Burris, J. L., Mathew, A. R., Schnoll, R. A., Rigotti, N. A., & Cummings, K. M. (2013) · Drugs · doi:10.1007/s40265-013-0038-y · Cited by 76
Adverse effects and tolerability of medications for the treatment of tobacco use and dependence
Hays, J. T., & Ebbert, J. O. (2010) · Drugs · doi:10.2165/11538190-000000000-00000 · Cited by 74
Gueye, A. B., Pryslawsky, Y., Trigo, J. M., Poulia, N., Delis, F., Antoniou, K., Loureiro, M., Laviolette, S. R., Vemuri, K., Makriyannis, A., et al. (2016) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyw068 · Cited by 74
Nicotine Vaccines to Assist with Smoking Cessation
Raupach, T., Hoogsteder, P., & van Schayck, O. C. P. (2012) · Drugs · doi:10.2165/11599900-000000000-00000 · Cited by 76
Hoogsteder, P., Kotz, D., van Spiegel, P. I., Viechtbauer, W., & van Schayck, O. C. P. (2014) · Addiction · doi:10.1111/add.12573 · Cited by 74
A bupropion smoking cessation clinical trial for cancer patients
Schnoll, R. A., Martinez, E., Tatum, K. L., Weber, D. M., Kuzla, N., Glass, M., Ridge, J. A., Langer, C. J., Miyamoto, C. T., Wileyto, E. P., et al. (2010) · Cancer Causes & Control · doi:10.1007/s10552-010-9507-8 · Cited by 76
Huang, L. Z., Campos, C., Ly, J., Carroll, F. I., & Quik, M. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2010.12.032 · Cited by 76
Maria, M. M. M., Hartwell, K. J., Hanlon, C. A., Canterberry, M., LeMatty, T., Owens, M. M., Brady, K. T., & George, M. S. (2014) · Addiction Biology · doi:10.1111/adb.12124 · Cited by 75
A Preliminary Benefit-Risk Assessment of Varenicline in Smoking Cessation
Cahill, K., Stead, L. F., & Lancaster, T. (2009) · Drug Safety · doi:10.2165/00002018-200932020-00005 · Cited by 73
King, C. C., Piper, M. E., Gepner, A. D., Fiore, M. C., Baker, T. B., & Stein, J. H. (2016) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.116.308728 · Cited by 77
Jimenez-Ruiz, C. A., Berlin, I., & Hering, T. (2009) · Drugs · doi:10.2165/00003495-200969100-00003 · Cited by 76
Hoogendoorn, M., Welsing, P. M. J., & Mölken, M. R. (2007) · Current Medical Research and Opinion · doi:10.1185/030079908x242917 · Cited by 72
Current and Emerging Pharmacotherapies for Cessation of Tobacco Smoking
Gómez‐Coronado, N., Walker, A. J., Berk, M., & Dodd, S. (2017) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2073 · Cited by 74
Nicotine receptor partial agonists for smoking cessation
Livingstone‐Banks, J., Fanshawe, T. R., Thomas, K. H., Theodoulou, A., Hajizadeh, A., Hartman, L., & Lindson, N. (2023) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006103.pub9 · Cited by 77
Nomura, A., Tanigawa, T., Muto, T., Oga, T., Fukushima, Y., Kiyosue, A., Miyazaki, M., Hida, E., & Satake, K. (2019) · Journal of Medical Internet Research · doi:10.2196/13520 · Cited by 73
Sterling, L. H., Windle, S. B., Filion, K. B., Touma, L., & Eisenberg, M. J. (2016) · Journal of the American Heart Association · doi:10.1161/jaha.115.002849 · Cited by 70
Bordia, T., Hrachova, M., Chin, M., McIntosh, J. M., & Quik, M. (2012) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.112.194852 · Cited by 70
Vaccination against nicotine: an emerging therapy for tobacco dependence
Maurer, P., & Bachmann, M. F. (2007) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.16.11.1775 · Cited by 70
Cigarette smoking and chronic kidney diseases
Nagasawa, Y., Yamamoto, R., Rakugi, H., & Isaka, Y. (2011) · Hypertension Research · doi:10.1038/hr.2011.205 · Cited by 70
Chronic Obstructive Pulmonary Disease
Nazir, S. A., & Erbland, M. L. (2009) · Drugs & Aging · doi:10.2165/11316760-000000000-00000 · Cited by 71
Rigotti, N. A., Gonzales, D. H., Dale, L. C., Lawrence, D. L., & Chang, Y. (2009) · Addiction · doi:10.1111/j.1360-0443.2008.02454.x · Cited by 71
Self-citationBupropion for Smoking Cessation in Patients With Acute Coronary Syndrome
Planer, D., Lev, I., Elitzur, Y., Sharon, N. A., Ouzan, E., Pugatsch, T., Chasid, M., Rom, M., & Lotan, C. (2011) · Archives of Internal Medicine · doi:10.1001/archinternmed.2011.72 · Cited by 69
Cellular, molecular, and genetic substrates underlying the impact of nicotine on learning
Gould, T. J., & Leach, P. T. (2013) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2013.08.004 · Cited by 72
Rodent models for nicotine withdrawal
Chellian, R., Behnood‐Rod, A., Bruijnzeel, D. M., Wilson, R., Pandy, V., & Bruijnzeel, A. W. (2021) · Journal of Psychopharmacology · doi:10.1177/02698811211005629 · Cited by 71
A review of the efficacy of smoking-cessation pharmacotherapies in nonwhite populations
Robles, G. I., Singh‐Franco, D., & Ghin, H. L. (2008) · Clinical Therapeutics · doi:10.1016/j.clinthera.2008.05.010 · Cited by 68
Rose, J. E., Herskovic, J. E., Behm, F. M., & Westman, E. C. (2009) · Nicotine & Tobacco Research · doi:10.1093/ntr/ntp103 · Cited by 68
Dunn, K. E., Sigmon, S. C., Reimann, E. F., Badger, G. J., Heil, S. H., & Higgins, S. T. (2010) · Experimental and Clinical Psychopharmacology · doi:10.1037/a0018649 · Cited by 69
Cui, Q., Robinson, L. L., Elston, D., Smaill, F., Cohen, J., Quan, C., McFarland, N., Thabane, L., McIvor, A., Zeidler, J. G., et al. (2011) · AIDS Patient Care and STDs · doi:10.1089/apc.2011.0199 · Cited by 68
Le Strat, Y., Rehm, J., & Le Foll, B. (2011) · Tobacco Control · doi:10.1136/tc.2010.038703 · Cited by 67
Coffin, P. O., Santos, G., Das, M., Santos, D., Huffaker, S., Matheson, T., Gasper, J. J., Vittinghoff, E., & Colfax, G. N. (2012) · Addiction · doi:10.1111/add.12073 · Cited by 67
Mills, E. J., Wu, P., Spurden, D., Ebbert, J. O., & Wilson, K. R. (2009) · Harm Reduction Journal · doi:10.1186/1477-7517-6-25 · Cited by 69
Varenicline for smoking cessation: efficacy, safety, and treatment recommendations
Ebbert, J. O. (2010) · Patient Preference and Adherence · doi:10.2147/ppa.s10620 · Cited by 67
Magnetic Resonance Imaging Studies of Cigarette Smoking
Azizian, A., Monterosso, J. R., O’Neill, J., & London, E. D. (2009) · Handbook of experimental pharmacology · doi:10.1007/978-3-540-69248-5_5 · Cited by 69
Correlates of smoking cessation in a nationally representative sample of U.S. adults
Arpana Agrawal, A., Sartor, C. E., Pergadia, M. L., Huizink, A. C., & Lynskey, M. T. (2008) · Addictive Behaviors · doi:10.1016/j.addbeh.2008.04.003 · Cited by 67
Mechanistic insights into nicotine withdrawal
Paolini, M., & De Biasi, M. (2011) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.07.075 · Cited by 66
Portugal, G. S., Kenney, J. W., & Gould, T. J. (2008) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2007.05.002 · Cited by 66
Sex as a biological variable: Drug use and abuse
Riley, A. L., Hempel, B. J., & Clasen, M. M. (2017) · Physiology & Behavior · doi:10.1016/j.physbeh.2017.10.005 · Cited by 66
Tonstad, S., Arons, C., Rollema, H., Berlin, I., Hájek, P., Fagerström, K. O., Els, C., McRae, T. D., & Russ, C. (2020) · Current Medical Research and Opinion · doi:10.1080/03007995.2020.1729708 · Cited by 66
Neurocognitive endophenotypes in schizophrenia: Modulation by nicotinic receptor systems
Mackowick, K. M., Barr, M. S., Wing, V. C., Rabin, R. A., Ouellet‐Plamondon, C., & George, T. P. (2013) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2013.07.010 · Cited by 65
Jackson, K. J., McLaughlin, J. P., Carroll, F. I., & Damaj, M. I. (2012) · Psychopharmacology · doi:10.1007/s00213-012-2716-y · Cited by 65
Treating Tobacco Dependence in a Medical Setting
Hurt, R. D., Ebbert, J. O., Hays, J. T., & McFadden, D. D. (2009) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.20031 · Cited by 66
Smoking cessation in patients with respiratory disease: existing treatments and future directions
Rigotti, N. A. (2013) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(13)70063-8 · Cited by 66
Consideration of sex and gender differences in addiction medication response
McKee, S. A., & McRae‐Clark, A. L. (2022) · Biology of Sex Differences · doi:10.1186/s13293-022-00441-3 · Cited by 67
Winhusen, T. M., Brigham, G. S., Kropp, F. B., Lindblad, R., Gardin, J. G., Penn, P., Hodgkins, C. C., Kelly, T. M., Douaihy, A. B., McCann, M., et al. (2013) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.13m08449 · Cited by 64
Effect of nicotine on body composition in mice
Mangubat, M., Lutfy, K., Lee, M. L., Pulido, L., Stout, D., Davis, R. C., Shin, C., Shahbazian, M., Seasholtz, S., Sinha‐Hikim, A. P., et al. (2011) · Journal of Endocrinology · doi:10.1530/joe-11-0350 · Cited by 64
Jackson, S. E., McGowan, J., Ubhi, H. K., Proudfoot, H., Shahab, L., Brown, J., & West, R. (2019) · Addiction · doi:10.1111/add.14549 · Cited by 65
Merz, C. N. B., Alberts, M. J., Balady, G. J., Ballantyne, C. M., Berra, K. A., Black, H. R., Blumenthal, R. S., Davidson, M. H., Fazio, S. B., Ferdinand, K. C., et al. (2009) · Circulation · doi:10.1161/circulationaha.109.192640 · Cited by 64
Cognitive Deficits in Schizophrenia: Focus on Neuronal Nicotinic Acetylcholine Receptors and Smoking
Ochoa, E. L. M., & Lasalde‐Dominicci, J. A. (2007) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-007-9149-x · Cited by 64
Crunelle, C. L., Miller, M. L., Booij, J., & van den Brink, W. (2009) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2009.11.001 · Cited by 66
Smoking Cessation Intervention: An Evidence-Based Approach
Laniado-Laborín, R. (2010) · Postgraduate Medicine · doi:10.3810/pgm.2010.03.2124 · Cited by 64
Effect of exercise type on smoking cessation: a meta-analysis of randomized controlled trials
Klinsophon, T., Thaveeratitham, P., Sitthipornvorakul, E., & Janwantanakul, P. (2017) · BMC Research Notes · doi:10.1186/s13104-017-2762-y · Cited by 63
Varenicline ameliorates nicotine withdrawal-induced learning deficits in C57BL/6 mice.
Raybuck, J. D., Portugal, G. S., Lerman, C., & Gould, T. J. (2008) · Behavioral Neuroscience · doi:10.1037/a0012601 · Cited by 62
ONWUZO, C. N., Olukorode, J., Sange, W., Orimoloye, D. A., Udojike, C., Omoragbon, L., Hassan, A. E., Falade, D. M., Omiko, R., Odunaike, O. S., et al. (2024) · Cureus · doi:10.7759/cureus.52102 · Cited by 61
Serotonin receptors as potential targets for modulation of nicotine use and dependence
Fletcher, P. J., LE, A., & Higgins, G. A. (2008) · Progress in brain research · doi:10.1016/s0079-6123(08)00918-7 · Cited by 61
Anthenelli, R. M., Blom, T. J., McElroy, S. L., & Keck, P. E. (2008) · Addiction · doi:10.1111/j.1360-0443.2008.02148.x · Cited by 61
Wilcox, C. S., Oskooilar, N., Erickson, J., Billes, S. K., Katz, B. B., Tollefson, G. D., & Dunayevich, E. (2009) · Addictive Behaviors · doi:10.1016/j.addbeh.2009.10.017 · Cited by 61
Nicotine reduces established levodopa‐induced dyskinesias in a monkey model of Parkinson's disease
Quik, M., Mallela, A., Ly, J., & Zhang, D. (2013) · Movement Disorders · doi:10.1002/mds.25594 · Cited by 60
Population pharmacokinetic analysis of varenicline in adult smokers
Ravva, P., Gastonguay, M. R., Tensfeldt, T. G., & Faessel, H. M. (2009) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2009.03520.x · Cited by 60
Efficacy of a nicotine mouth spray in smoking cessation: a randomised, double-blind trial
Tønnesen, P., Lauri, H., Perfekt, R., Mann, K. F., & Batra, A. (2012) · European Respiratory Journal · doi:10.1183/09031936.00155811 · Cited by 61
Qaseem, A., Fihn, S. D., Dallas, P., Williams, S., Owens, D. K., & Shekelle, P. (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-157-10-201211200-00011 · Cited by 60
Smoking Cessation in Pregnancy: Why, How, and What Next…
Crawford, J. T., Tolosa, J. E., & Goldenberg, R. L. (2008) · Clinical Obstetrics & Gynecology · doi:10.1097/grf.0b013e31816fe9e9 · Cited by 61
What have we learned from large drug treatment trials in COPD?
Calverley, P. M. A., & Rennard, S. I. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61381-6 · Cited by 60
Knight, C., Howard, P., Baker, C. L., & Marton, J. P. (2009) · Value in Health · doi:10.1111/j.1524-4733.2009.00672.x · Cited by 59
Falk, D. E., Castle, I. P., Ryan, M., Fertig, J. B., & Litten, R. Z. (2015) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000000133 · Cited by 61
McAfee, T. A. (2007) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2007.09.011 · Cited by 59
Nicotinic Receptor Contributions to Smoking: Insights from Human Studies and Animal Models
Brunzell, D. H., Stafford, A. M., & Dixon, C. I. (2015) · Current Addiction Reports · doi:10.1007/s40429-015-0042-2 · Cited by 58
Hájek, P., Smith, K. M., Dhanji, A., & McRobbie, H. J. (2013) · BMC Medicine · doi:10.1186/1741-7015-11-140 · Cited by 59
Metadata
- Authors
- Gonzales, D.
- Affiliations
- Oregon Health & Science University (US)
- Corresponding author
- Gonzales, David
- ORCID
- Gonzales, David
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2006-07-05
- Volume
- 296
- Issue
- 1
- Pages
- 47
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2107200746
- Cited by
- 1,361
- References
- 29
- Citations by year
- 2026: 32 · 2025: 21 · 2024: 25 · 2023: 25 · 2022: 34 · 2021: 26 · 2020: 52 · 2019: 49 · 2018: 41 · 2017: 51 · 2016: 50 · 2015: 70 · 2014: 74 · 2013: 80 · 2012: 94
- FWCI
- 85.72
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- JAMA (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Oregon Health and Science University
- Cardinal Health
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Smoking Behavior and Cessation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nicotinic Acetylcholine Receptors Study
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Keywords
- varenicline, bupropion sustained release, smoking cessation, α4β2 nicotinic acetylcholine receptor, partial agonists, nicotine dependence, continuous abstinence, exhaled carbon monoxide, brief counseling, nicotine replacement therapy, drug safety, adverse events, relapse, nicotine withdrawal symptoms, nicotine self-administration
- MeSH terms
- Varenicline, Adult, Benzazepines, Delayed-Action Preparations, Double-Blind Method, Female, Humans, Male, Middle Aged, Quinoxalines, Receptors, Nicotinic, Smoking Cessation, Bupropion, Nicotinic Agonists, Dopamine Uptake Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
